

Judit Morello

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2945001/publications.pdf>

Version: 2024-02-01

48
papers

1,147
citations

393982

19
h-index

395343

33
g-index

49
all docs

49
docs citations

49
times ranked

1467
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Cysteine as a Multifaceted Player in Kidney, the Cysteine-Related Thiols and Its Implications for Precision Medicine. <i>Molecules</i> , 2022, 27, 1416. | 1.7 | 10 |
| 2 | Synthetic Red Blood Cell-Specific Glycolytic Intermediate 2,3-Diphosphoglycerate (2,3-DPG) Inhibits <i>Plasmodium falciparum</i> Development In Vitro. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 840968. | 1.8 | 4 |
| 3 | AHR canonical pathway: in vivo findings to support novel antihypertensive strategies. <i>Pharmacological Research</i> , 2021, 165, 105407. | 3.1 | 12 |
| 4 | A simple method to measure sulfonation in man using paracetamol as probe drug. <i>Scientific Reports</i> , 2021, 11, 9036. | 1.6 | 1 |
| 5 | Phenotyping SULT in Man: a Simple Metric Using Paracetamol as Probe. <i>FASEB Journal</i> , 2021, 35, . | 0.2 | 0 |
| 6 | Aryl Hydrocarbon Receptor and Cysteine Redox Dynamics Underlie (Mal)adaptive Mechanisms to Chronic Intermittent Hypoxia in Kidney Cortex. <i>Antioxidants</i> , 2021, 10, 1484. | 2.2 | 9 |
| 7 | A Mechanistic-Based and Non-invasive Approach to Quantify the Capability of Kidney to Detoxify Cysteine-Disulfides. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1306, 109-120. | 0.8 | 3 |
| 8 | <p>Metabolic Dysfunction and Asthma: Current Perspectives</p>. <i>Journal of Asthma and Allergy</i> , 2020, Volume 13, 237-247. | 1.5 | 24 |
| 9 | A Metabolomics-Inspired Strategy for the Identification of Protein Covalent Modifications. <i>Frontiers in Chemistry</i> , 2019, 7, 532. | 1.8 | 6 |
| 10 | The mercapturomic profile of health and non-communicable diseases. <i>High-Throughput</i> , 2019, 8, 10. | 4.4 | 7 |
| 11 | Mass Spectrometry-Based Methodologies for Targeted and Untargeted Identification of Protein Covalent Adducts (Adductomics): Current Status and Challenges. <i>High-Throughput</i> , 2019, 8, 9. | 4.4 | 17 |
| 12 | Mercapturate Pathway in the Tubulocentric Perspective of Diabetic Kidney Disease. <i>Nephron</i> , 2019, 143, 17-23. | 0.9 | 17 |
| 13 | Severe Acute Kidney Injury and Double Tubulopathy Due to Dual Toxicity Caused by Combination Antiretroviral Therapy. <i>Kidney International Reports</i> , 2019, 4, 494-499. | 0.4 | 13 |
| 14 | Usefulness of zebrafish larvae to evaluate drug-induced functional and morphological renal tubular alterations. <i>Archives of Toxicology</i> , 2018, 92, 411-423. | 1.9 | 39 |
| 15 | Zebrafish Larvae Are a Suitable Model to Investigate the Metabolic Phenotype of Drug-Induced Renal Tubular Injury. <i>Frontiers in Pharmacology</i> , 2018, 9, 1193. | 1.6 | 13 |
| 16 | The first-line antiepileptic drug carbamazepine: Reaction with biologically relevant free radicals. <i>Free Radical Biology and Medicine</i> , 2018, 129, 559-568. | 1.3 | 9 |
| 17 | Implications of sulfotransferase activity in interindividual variability in drug response: clinical perspective on current knowledge. <i>Drug Metabolism Reviews</i> , 2017, 49, 357-371. | 1.5 | 25 |
| 18 | Exploratory metabolomics study of the experimental opisthorchiasis in a laboratory animal model (golden hamster, <i>Mesocricetus auratus</i>). <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0006044. | 1.3 | 15 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Effect of Suboptimal Sampling and Handling Conditions on Urinary Metabolic Profiles. <i>Chromatographia</i> , 2015, 78, 429-434. | 0.7 | 2 |
| 20 | Monitoring of the lactonase activity of paraoxonase-1 enzyme in HIV-1-infection. <i>Journal of the International AIDS Society</i> , 2014, 17, 19682. | 1.2 | 3 |
| 21 | Plasma Raltegravir Exposure Influences the Antiviral Activity and Selection of Resistance Mutations. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 156-164. | 0.5 | 18 |
| 22 | Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia in HIV/HCV-Coinfected Patients With All HCV Genotypes. <i>Journal of Infectious Diseases</i> , 2012, 205, 376-383. | 1.9 | 31 |
| 23 | Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 457-477. | 1.5 | 36 |
| 24 | Noncirrhotic portal hypertension in HIV infection. <i>Current Opinion in Infectious Diseases</i> , 2011, 24, 12-18. | 1.3 | 34 |
| 25 | Short Communication: Use of Serum Bilirubin Levels as Surrogate Marker of Early Virological Response to Atazanavir-Based Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 1043-1045. | 0.5 | 11 |
| 26 | Impact of Inosine Triphosphatase Gene Variants on the Risk of Anemia in HIV/Hepatitis C Virus-Coinfected Patients Treated for Chronic Hepatitis C. <i>Clinical Infectious Diseases</i> , 2011, 53, 1291-1295. | 2.9 | 16 |
| 27 | Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B*5701. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1567-1569. | 1.3 | 33 |
| 28 | Influence of a Single Nucleotide Polymorphism at the Main Ribavirin Transporter Gene on the Rapid Virological Response to Pegylated Interferon+Ribavirin Therapy in Patients with Chronic Hepatitis C Virus Infection. <i>Journal of Infectious Diseases</i> , 2010, 202, 1185-1191. | 1.9 | 33 |
| 29 | Preemptive Erythropoietin Plus High Ribavirin Doses to Increase Rapid Virological Responses in HIV Patients Treated for Chronic Hepatitis C. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 419-424. | 0.5 | 6 |
| 30 | Plasma Ribavirin Trough Concentrations at Week 4 Predict Hepatitis C Virus (HCV) Relapse in HIV-HCV-Coinfected Patients Treated for Chronic Hepatitis C. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1647-1649. | 1.4 | 23 |
| 31 | Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients. <i>Aids</i> , 2010, 24, 777-779. | 1.0 | 11 |
| 32 | Rate and Predictors of Success in the Retreatment of Chronic Hepatitis C Virus in HIV/Hepatitis C Virus Coinfected Patients With Prior Nonresponse or Relapse. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 53, 364-368. | 0.9 | 27 |
| 33 | The Benefit of Simplification From Tipranavir/Ritonavir 500/200 bid to 500/100 bid Guided by Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 242-244. | 1.0 | 0 |
| 34 | Use of Different Inhibitory Quotients To Predict Early Virological Response to Tipranavir in Antiretroviral-Experienced Human Immunodeficiency Virus-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 4153-4158. | 1.4 | 6 |
| 35 | Predictors of Kidney Tubular Dysfunction in HIV-Infected Patients Treated with Tenofovir: A Pharmacogenetic Study. <i>Clinical Infectious Diseases</i> , 2009, 48, e108-e116. | 2.9 | 221 |
| 36 | Differences in Lopinavir Plasma Concentrations Comparing Kaletra Film Coated Tablets and Soft Gelatine Capsules That Result in Various Lipid Abnormalities. <i>Drug Metabolism Letters</i> , 2009, 3, 67-69. | 0.5 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Raltegravir and Etravirine Are Active against HIV Type 1 Group O. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 225-227. | 0.5 | 41 |
| 38 | Role of atazanavir in the treatment of HIV infection. <i>Therapeutics and Clinical Risk Management</i> , 2009, 5, 99-116. | 0.9 | 11 |
| 39 | Short Communication: Association between Tipranavir Plasma Levels and Virological Response in HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 389-391. | 0.5 | 3 |
| 40 | Switch from Ritonavir-Boosted to Unboosted Atazanavir Guided by Therapeutic Drug Monitoring. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 821-825. | 0.5 | 39 |
| 41 | Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 816-822. | 1.3 | 39 |
| 42 | Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1174-1180. | 1.3 | 78 |
| 43 | Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin. <i>Aids</i> , 2008, 22, 2535-2537. | 1.0 | 36 |
| 44 | Distinct Hepatitis C virus Kinetics in HIV-Infected Patients Treated with Ribavirin plus Either Pegylated Interferon α 2a or α 2b. <i>Antiviral Therapy</i> , 2008, 13, 511-517. | 0.6 | 5 |
| 45 | Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 61, 200-205. | 1.3 | 70 |
| 46 | Drug Interactions of Tipranavir, a New HIV Protease Inhibitor. <i>Drug Metabolism Letters</i> , 2007, 1, 81-84. | 0.5 | 10 |
| 47 | Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 839-850. | 0.9 | 19 |
| 48 | Measurement of Ribavirin Plasma Concentrations by High-performance Liquid Chromatography Using a Novel Solid-phase Extraction Method in Patients Treated for Chronic Hepatitis C. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 802-806. | 1.0 | 28 |